Editas Medicine 향후 성장

Future 기준 점검 0/6

Editas Medicine 의 수익은 연간 34.1% 감소할 것으로 예상되는 반면, 연간 수익은 5.1% 로 증가할 것으로 예상됩니다. EPS는 연간 24.5% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 -132% 로 예상됩니다.

핵심 정보

5.1%

이익 성장률

24.51%

EPS 성장률

Biotechs 이익 성장	23.9%
매출 성장률	-34.1%
향후 자기자본이익률	-132.01%
애널리스트 커버리지	Good
마지막 업데이트	24 Nov 2025

최근 향후 성장 업데이트

Analysts Are Upgrading Editas Medicine, Inc. (NASDAQ:EDIT) After Its Latest Results

Nov 13

Recent updates

Analysts Are Upgrading Editas Medicine, Inc. (NASDAQ:EDIT) After Its Latest Results

Nov 13

Lacklustre Performance Is Driving Editas Medicine, Inc.'s (NASDAQ:EDIT) 29% Price Drop

Nov 05

Here's Why We're A Bit Worried About Editas Medicine's (NASDAQ:EDIT) Cash Burn Situation

Nov 02

Editas Medicine: Three Strikes And It's Out, Or Third Time's The Charm?

Oct 14

Editas Medicine, Inc. (NASDAQ:EDIT) Stock Catapults 26% Though Its Price And Business Still Lag The Industry

Sep 09

There's Reason For Concern Over Editas Medicine, Inc.'s (NASDAQ:EDIT) Massive 42% Price Jump

Jul 22

Editas Medicine (NASDAQ:EDIT) Will Have To Spend Its Cash Wisely

Jun 17

Editas Medicine, Inc.'s (NASDAQ:EDIT) Price Is Right But Growth Is Lacking After Shares Rocket 28%

May 21

Editas Medicine, Inc. (NASDAQ:EDIT) Looks Inexpensive After Falling 35% But Perhaps Not Attractive Enough

Mar 30

We're A Little Worried About Editas Medicine's (NASDAQ:EDIT) Cash Burn Rate

Mar 13

Editas And Intellia: Strategic Shifts And Long-Term Investment Potential

Jan 17

Little Excitement Around Editas Medicine, Inc.'s (NASDAQ:EDIT) Revenues As Shares Take 34% Pounding

Nov 20

Analysts Are Betting On Editas Medicine, Inc. (NASDAQ:EDIT) With A Big Upgrade This Week

Nov 06

Is Editas Medicine (NASDAQ:EDIT) In A Good Position To Invest In Growth?

Sep 26

Editas Medicine: A Risk/Reward Worth Considering

Sep 25

Benign Growth For Editas Medicine, Inc. (NASDAQ:EDIT) Underpins Stock's 32% Plummet

Aug 23

Editas Medicine, Inc. (NASDAQ:EDIT) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Aug 10

Analysts Have Lowered Expectations For Editas Medicine, Inc. (NASDAQ:EDIT) After Its Latest Results

May 12

The Market Doesn't Like What It Sees From Editas Medicine, Inc.'s (NASDAQ:EDIT) Revenues Yet As Shares Tumble 25%

Apr 23

Editas Medicine, Inc. (NASDAQ:EDIT) Surges 28% Yet Its Low P/S Is No Reason For Excitement

Mar 09

Editas Medicine: Several Catalysts For Reni-Cel In 2024 Make This A Must Watch

Feb 28

New Forecasts: Here's What Analysts Think The Future Holds For Editas Medicine, Inc. (NASDAQ:EDIT)

Dec 15

Broker Revenue Forecasts For Editas Medicine, Inc. (NASDAQ:EDIT) Are Surging Higher

May 10

Is Editas Medicine (NASDAQ:EDIT) In A Good Position To Invest In Growth?

Jan 19

이익 및 매출 성장 예측

NasdaqGS:EDIT - 애널리스트 향후 추정치 및 과거 재무 데이터 (USD Millions)
날짜	매출	이익	자유현금흐름	영업현금흐름	평균 애널리스트 수
12/31/2027	14	-143	-150	-150	7
12/31/2026	17	-125	-128	-126	13
12/31/2025	24	-179	-176	-176	13
9/30/2025	46	-200	-181	-180	N/A
6/30/2025	39	-237	-205	-201	N/A
3/31/2025	36	-251	-215	-208	N/A
12/31/2024	32	-237	-219	-210	N/A
9/30/2024	62	-211	-191	-182	N/A
6/30/2024	67	-193	-172	-165	N/A
3/31/2024	69	-166	-151	-146	N/A
12/31/2023	78	-153	-137	-132	N/A
9/30/2023	25	-195	-156	-152	N/A
6/30/2023	19	-206	-169	-165	N/A
3/31/2023	23	-219	-168	-164	N/A
12/31/2022	20	-220	-181	-177	N/A
9/30/2022	26	-201	-176	-170	N/A
6/30/2022	32	-184	-171	-162	N/A
3/31/2022	26	-186	-174	-164	N/A
12/31/2021	26	-193	-172	-164	N/A
9/30/2021	24	-214	-176	-169	N/A
6/30/2021	81	-167	-189	-183	N/A
3/31/2021	92	-135	-180	-175	N/A
12/31/2020	91	-116	-187	-180	N/A
9/30/2020	92	-91	-106	-99	N/A
6/30/2020	33	-132	-79	-71	N/A
3/31/2020	24	-142	-73	-66	N/A
12/31/2019	21	-134	-47	-41	N/A
9/30/2019	14	-121	-86	-80	N/A
6/30/2019	25	-103	N/A	-61	N/A
3/31/2019	30	-108	N/A	-52	N/A
12/31/2018	32	-110	N/A	-46	N/A
9/30/2018	29	-121	N/A	-72	N/A
6/30/2018	21	-132	N/A	-92	N/A
3/31/2018	17	-120	N/A	-102	N/A
12/31/2017	14	-120	N/A	-9	N/A
9/30/2017	11	-124	N/A	2	N/A
6/30/2017	6	-118	N/A	13	N/A
3/31/2017	6	-111	N/A	29	N/A
12/31/2016	6	-97	N/A	-50	N/A
9/30/2016	6	-71	N/A	-45	N/A
6/30/2016	6	-57	N/A	-39	N/A
3/31/2016	2	-86	N/A	-9	N/A
12/31/2015	2	-73	N/A	-5	N/A
9/30/2015	1	-66	N/A	-1	N/A
6/30/2015	0	-62	N/A	9	N/A
3/31/2015	N/A	-17	N/A	-13	N/A

애널리스트 향후 성장 전망

수입 대 저축률: EDIT 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 vs 시장: EDIT 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

고성장 수익: EDIT 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 대 시장: EDIT 의 수익은 향후 3년간 감소할 것으로 예상됩니다(연간 -34.1%).

고성장 매출: EDIT 의 수익은 향후 3년 동안 감소할 것으로 예상됩니다(연간 -34.1%).

주당순이익 성장 예측

향후 자기자본이익률

미래 ROE: EDIT는 3년 뒤에도 수익성이 없을 것으로 전망됩니다.

성장 기업 찾아보기

기업 분석 및 재무 데이터 상태

데이터	최종 업데이트 (UTC 시간)
기업 분석	2025/12/24 02:19
종가	2025/12/24 00:00
수익	2025/09/30
연간 수익	2024/12/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
기업 재무제표	10년	손익계산서 현금흐름표 대차대조표	SEC 양식 10-K SEC 양식 10-Q
분석가 컨센서스 추정치	+3년	재무 예측 분석가 목표주가	분석가 리서치 보고서 Blue Matrix
시장 가격	30년	주가 배당, 분할 및 기타 조치	ICE 시장 데이터 SEC 양식 S-1
지분 구조	10년	주요 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
경영진	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발	10년	회사 공시	SEC 양식 8-K

^* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 Github 페이지에서 확인할 수 있으며, 보고서 활용 방법에 대한 가이드와 Youtube 튜토리얼도 제공합니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

Editas Medicine, Inc.는 26명의 분석가가 다루고 있습니다. 이 중 13명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가	기관
Jack Allen	Baird
Joel Beatty	Baird
Huidong Wang	Barclays

Editas Medicine 향후 성장

Future 기준 점검 0/6

핵심 정보

최근 향후 성장 업데이트

Price target increased by 32% to US$5.13

Analysts Are Upgrading Editas Medicine, Inc. (NASDAQ:EDIT) After Its Latest Results

Consensus revenue estimates increase by 35%, EPS downgraded

Consensus revenue estimates increase by 17%, EPS downgraded

Consensus revenue estimates increase by 78%

Price target decreased by 7.1% to US$13.00

Recent updates

Price target increased by 32% to US$5.13

Analysts Are Upgrading Editas Medicine, Inc. (NASDAQ:EDIT) After Its Latest Results

Third quarter 2025 earnings: EPS and revenues exceed analyst expectations

New minor risk - Shareholder dilution

Lacklustre Performance Is Driving Editas Medicine, Inc.'s (NASDAQ:EDIT) 29% Price Drop

Here's Why We're A Bit Worried About Editas Medicine's (NASDAQ:EDIT) Cash Burn Situation

Editas Medicine: Three Strikes And It's Out, Or Third Time's The Charm?

Editas Medicine Reports in Vivo Proof-Of-Concept Data for Edit-401 At the European Society of Gene and Cell Therapy (Esgct) 32Nd Annual Congress

Editas Medicine, Inc. (NASDAQ:EDIT) Stock Catapults 26% Though Its Price And Business Still Lag The Industry

Consensus revenue estimates increase by 35%, EPS downgraded

New minor risk - Financial position

Second quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behind

There's Reason For Concern Over Editas Medicine, Inc.'s (NASDAQ:EDIT) Massive 42% Price Jump

Editas Medicine (NASDAQ:EDIT) Will Have To Spend Its Cash Wisely

Editas Medicine Reports Proprietary Targeted Lipid Nanoparticle Delivery in Non-Human Primates Enables in Vivo HBG1/2 Promoter Editing for Sickle Cell Disease and Beta Thalassemia At the European Hematology Association 2025 Congress in June

Editas Medicine, Inc.'s (NASDAQ:EDIT) Price Is Right But Growth Is Lacking After Shares Rocket 28%

Consensus revenue estimates increase by 17%, EPS downgraded

Editas Medicine, Inc. Reports New in Vivo Proof of Concept Data in an Undisclosed Liver Target At the American Society of Gene and Cell Therapy Annual Meeting

First quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behind

Editas Medicine, Inc. to Report Q1, 2025 Results on May 12, 2025

Editas Medicine to Present Preclinical Data Demonstrating Progress in the Development of an in vivo Gene Editing Pipeline at the American Society of Gene and Cell Therapy Annual Meeting

Editas Medicine, Inc., Annual General Meeting, May 29, 2025

New minor risk - Market cap size

Editas Medicine, Inc. (NASDAQ:EDIT) Looks Inexpensive After Falling 35% But Perhaps Not Attractive Enough

We're A Little Worried About Editas Medicine's (NASDAQ:EDIT) Cash Burn Rate

President notifies of intention to sell stock

Editas Medicine, Inc. to Report Q4, 2024 Results on Mar 05, 2025

Editas And Intellia: Strategic Shifts And Long-Term Investment Potential

Editas Medicine, Inc. to Eliminate Approximately 65% of its Workforce over the Next Six Months

Little Excitement Around Editas Medicine, Inc.'s (NASDAQ:EDIT) Revenues As Shares Take 34% Pounding

Consensus revenue estimates increase by 78%

Analysts Are Betting On Editas Medicine, Inc. (NASDAQ:EDIT) With A Big Upgrade This Week

Second quarter 2024 earnings released: US$0.82 loss per share (vs US$0.56 loss in 2Q 2023)

New major risk - Revenue and earnings growth

Price target decreased by 7.1% to US$13.00

Editas Medicine, Inc. Announces Achievement of in Vivo Preclinical Proof of Concept

Is Editas Medicine (NASDAQ:EDIT) In A Good Position To Invest In Growth?

Editas Medicine: A Risk/Reward Worth Considering

Benign Growth For Editas Medicine, Inc. (NASDAQ:EDIT) Underpins Stock's 32% Plummet

Consensus revenue estimates fall by 13%

New major risk - Revenue and earnings growth

Editas Medicine, Inc. (NASDAQ:EDIT) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

New minor risk - Insider selling

Executive VP & Chief Scientific Officer recently sold US$64k worth of stock

Executive VP & Chief Medical Officer notifies of intention to sell stock

New minor risk - Share price stability

Editas Medicine Announces New Safety and Efficacy Data from the Edithal Trial of Reni-Cel in 7 Patients with Transfusion-Dependent Beta Thalassemia, Presented At the European Hematology Association (Eha) Annual Congress

President recently sold US$67k worth of stock

President notifies of intention to sell stock

CFO & Executive VP recently sold US$125k worth of stock

Independent Lead Director recently bought US$254k worth of stock

Consensus revenue estimates fall by 16%

Analysts Have Lowered Expectations For Editas Medicine, Inc. (NASDAQ:EDIT) After Its Latest Results

First quarter 2024 earnings: EPS and revenues miss analyst expectations

The Market Doesn't Like What It Sees From Editas Medicine, Inc.'s (NASDAQ:EDIT) Revenues Yet As Shares Tumble 25%

Editas Medicine, Inc., Annual General Meeting, May 30, 2024

President recently sold US$733k worth of stock

Editas Medicine, Inc. (NASDAQ:EDIT) Surges 28% Yet Its Low P/S Is No Reason For Excitement

President notifies of intention to sell stock

Consensus revenue estimates increase by 49%, EPS downgraded

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Editas Medicine: Several Catalysts For Reni-Cel In 2024 Make This A Must Watch

New Forecasts: Here's What Analysts Think The Future Holds For Editas Medicine, Inc. (NASDAQ:EDIT)

Consensus revenue estimates increase by 25%

Editas Medicine, Inc. Announces New EDIT-301 Safety And Efficacy Data In 17 Patients, Presented At The American Society Of Hematology (ASH) Annual Meeting And In A Company-Sponsored Webinar

New minor risk - Share price stability

Consensus revenue estimates increase by 21%

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations